Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
Streptomyces have been presented as a great source of antibiotics and anti-cancer drugs over the past century. Especially Streptomyces living in adverse conditions produce certain metabolites with cytolytic and anti-microbial activities, which have been utilised for manufacturing antimicrobial and a...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
2024-01-01
|
| Series: | Scripta Medica |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406775K.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096602744946688 |
|---|---|
| author | Kaur Prabhjot Bhandari Divya Dhawal Chopra Hitesh |
| author_facet | Kaur Prabhjot Bhandari Divya Dhawal Chopra Hitesh |
| author_sort | Kaur Prabhjot |
| collection | DOAJ |
| description | Streptomyces have been presented as a great source of antibiotics and anti-cancer drugs over the past century. Especially Streptomyces living in adverse conditions produce certain metabolites with cytolytic and anti-microbial activities, which have been utilised for manufacturing antimicrobial and anticancer drugs. Doxorubicin (DOX) is a potent anti-cancer drug derived from Streptomyces, that is widely used for various cancers, including cancers of the ovary, urinary bladder, GI tract, breast, thyroid gland, lung, bone, kidney (nephroblastoma) and blood (leukaemia). This anthracycline antibiotic is limited by its adverse effect profile, with the main adverse effects being nausea, vomiting, alopecia, infertility, cardiotoxicity, myelosuppression and nephrotoxicity. Nanoparticle delivery systems present a good solution to avoid adverse effects. Some nano-based formulations have reached the clinics, while many new ones in the pipeline show promising results. This review attempts to compile the existing literature on the clinical status of DOX highlight the need for the development of nanoparticles (NPs) that may serve as drug delivery agents, imaging probes and other multifunctional particulates. The integration of nanotechnology with Streptomyces-derived compounds can help shape the anti-cancer therapy of the future. |
| format | Article |
| id | doaj-art-9b48499b72134de28af4d995b9640be3 |
| institution | Kabale University |
| issn | 2490-3329 2303-7954 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine |
| record_format | Article |
| series | Scripta Medica |
| spelling | doaj-art-9b48499b72134de28af4d995b9640be32025-02-05T13:19:48ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542024-01-0155677578610.5937/scriptamed55-522072490-33292406775KStreptomyces-derived nano-doxorubicin: Clinical status and patents grantedKaur Prabhjot0https://orcid.org/0000-0002-9781-6668Bhandari Divya Dhawal1https://orcid.org/0000-0002-2813-0267Chopra Hitesh2https://orcid.org/0000-0001-8867-7603Chandigarh College of Pharmacy, Landran, Mohali, IndiaPanjab University, University Institute of Pharmaceutical Sciences, Chandigarh, IndiaSaveetha Institute of Medical and Technical Sciences, Saveetha School of Engineering, Department of Biosciences, Chennai, Tamil Nadu, IndiaStreptomyces have been presented as a great source of antibiotics and anti-cancer drugs over the past century. Especially Streptomyces living in adverse conditions produce certain metabolites with cytolytic and anti-microbial activities, which have been utilised for manufacturing antimicrobial and anticancer drugs. Doxorubicin (DOX) is a potent anti-cancer drug derived from Streptomyces, that is widely used for various cancers, including cancers of the ovary, urinary bladder, GI tract, breast, thyroid gland, lung, bone, kidney (nephroblastoma) and blood (leukaemia). This anthracycline antibiotic is limited by its adverse effect profile, with the main adverse effects being nausea, vomiting, alopecia, infertility, cardiotoxicity, myelosuppression and nephrotoxicity. Nanoparticle delivery systems present a good solution to avoid adverse effects. Some nano-based formulations have reached the clinics, while many new ones in the pipeline show promising results. This review attempts to compile the existing literature on the clinical status of DOX highlight the need for the development of nanoparticles (NPs) that may serve as drug delivery agents, imaging probes and other multifunctional particulates. The integration of nanotechnology with Streptomyces-derived compounds can help shape the anti-cancer therapy of the future.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406775K.pdfdoxorubicinnanostructuresstreptomycesnanoparticlesmicrobial |
| spellingShingle | Kaur Prabhjot Bhandari Divya Dhawal Chopra Hitesh Streptomyces-derived nano-doxorubicin: Clinical status and patents granted Scripta Medica doxorubicin nanostructures streptomyces nanoparticles microbial |
| title | Streptomyces-derived nano-doxorubicin: Clinical status and patents granted |
| title_full | Streptomyces-derived nano-doxorubicin: Clinical status and patents granted |
| title_fullStr | Streptomyces-derived nano-doxorubicin: Clinical status and patents granted |
| title_full_unstemmed | Streptomyces-derived nano-doxorubicin: Clinical status and patents granted |
| title_short | Streptomyces-derived nano-doxorubicin: Clinical status and patents granted |
| title_sort | streptomyces derived nano doxorubicin clinical status and patents granted |
| topic | doxorubicin nanostructures streptomyces nanoparticles microbial |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2024/2490-33292406775K.pdf |
| work_keys_str_mv | AT kaurprabhjot streptomycesderivednanodoxorubicinclinicalstatusandpatentsgranted AT bhandaridivyadhawal streptomycesderivednanodoxorubicinclinicalstatusandpatentsgranted AT choprahitesh streptomycesderivednanodoxorubicinclinicalstatusandpatentsgranted |